STL Index for: Minocycline

Sarecycline: A Narrow-Spectrum Antibiotic

Sarecycline is a novel antibiotic that has shown significant promise in acne treatment due to its narrow-spectrum activity and weight-based dosing.

Rosacea: An Update in Diagnosis, Classification and Management

This review details the rosacea phenotype approach to diagnosis and classification, and summarizes current evidence-based treatment recommendations for individual features.

Skin Treatments Introduced in 2020

This index covers all new skin treatments introduced in Skin Therapy Letter Dermatology Edition articles in 2020.

Update on Drugs & Devices: September-October 2020

This update covers: Guselkumab SC use (Tremfya®), Adalimumab-fkjp SC use (Hulio®), Collagenase clostridium histolyticum-aaes SC use (Qwo™), Protein replacement therapy for XLHED (ER-004), Pembrolizumab IV use (Keytruda®), Minocycline 1.5% foam (Zilxi™), Microbiome-based non-aqueous ointment (ATR-12), Dupilumab SC use (Dupixent®) and Selumetinib capsules (Koselugo™)

Skin Treatments Introduced in 2019

A variety of new skin treatments introduced in 2019.

Update on Drugs & Devices: January – February 2020

This update covers Lebrikizumab SC injection (Dermira), Infliximab-axxq for IV injection (Avsola™, Amgen), Trifarotene cream 50 mcg/g (Aklief®, Galderma), Adalimumab-afzb for SC injection (Abrilada™, Pfizer), Lidocaine + tetracaine (7%/7%) local anesthetic cream (Pliaglis®, Crescita Therapeutics), Maralixibat oral solution (Mirum Pharmaceuticals), Cetirizine hydrochloride for IV injection (Quzyttir™, TerSera Therapeutics) and Minocycline foam 4% (Amzeeq™, Foamix)

Update on the Management of Vitiligo

Vitiligo is a psychosocially debilitating disease requiring a multidisciplinary approach to treatment. Patients should be made aware of all of the options available geared at repigmentation and depigmentation prior to formulating a treatment plan.

A Clinician’s Guide to Treating Acne

In this article, we provide a guide to address a growing need by primary care physicians to have a logical and practical approach to treating various forms of acne.

Skin and Diet: An Update on the Role of Dietary Change as a Treatment Strategy for Skin Disease

An increasing body of research indicates that dietary change may serve as a component of therapy for certain skin conditions. This includes conditions such as acne, atopic dermatitis, aging skin, psoriasis, and rosacea. This article takes a high level overview of the role that diet may play in these conditions.

A Physician’s Guide to Treating Acne

Acne is among the most common dermatological conditions seen in primary care. In this article, we provide a guide to address a growing need by primary care physicians to have a logical and practical approach to treating various forms of acne.

Rosacea: An Update on Medical Therapies

Rosacea is a common, chronic cutaneous condition that affects the face. Various conventional and emerging therapies for rosacea are reviewed.

A Controversial Proposal: No More Antibiotics for Acne!

Administration of antibiotics, often for prolonged periods, has become the standard of care for acne. The authors provide current evidence to suggest that dermatologists should consider a departure from standard operating procedure by curtailing, if not discontinuing, the routine and regular use of antibiotics for acne.

Antibiotic Resistance in Acne Treatment

Propionibacterium acnes (P. acnes) is an anaerobic bacteria implicated in the pathogenesis of acne. Current treatment guidelines offer strategies to limit the potential for resistance while achieving optimal outcome in the management of inflammatory and non-inflammatory acne.

Oral Antibiotics: Minocycline

Minocycline is a tetracycline antibiotic, which is often used for acne treatment for its anti-bacterial and anti-inflammatory effects. The mechanism of action, side-effects, and drug interactions are discussed.

Minocycline as Acne Treatment Option

Minocycline is a tetracycline antibiotic which is used for acne treatment. This article provides an overview of minocycline, side-effects, brands, and drug interactions are discussed.

Cutaneous Reactions to Anticancer Agents Targeting the Epidermal Growth Factor Receptor: A Dermatology-Oncology Perspective

The epidermal growth factor receptor (EGFR) is often overexpressed or dysregulated in solid tumors. Targeting the EGFR-mediated signaling pathway has become routine practice in the treatment of lung, pancreatic, head and neck, and colon carcinomas.

Minocycline (Minocin®, Dynacin®, Vectrin®) Clinical Experience and Patient Profile

Suitable and unsuitable patient profiles for minocycline is discussed in this article. Important takeaways from clinical experience with minocycline is also in this article.

Minocycline (Minocin®, Dynacin®, Vectrin®) Indications

Dermatological and non-dermatological indications for minocycline ((Minocin®, Dynacin®, Vectrin®) are discussed in depth in this article.

Minocycline: Dosing, Efficacy, Compliance and Cost of Treatment

Minocycline antibiotics are used to treat acne, rosacea, and perioral dermatitis. Considerations like appropriate dosing, cost of treatments, and patient compliance issues are discussed as well as efficacy.

Minocycline (Minocin, Dynacin, Vectrin) Side Effects, Safety and Risks

Side effects, safety and risks of Minocycline (Minocin, Dynacin, Vectrin) are discussed in this article. Topics include drug interactions, bacterial resistance, as well as other adverse effects.

Systemic Therapy for Rosacea

Rosacea is a common condition that affects people of all races. More aggressive and innovative uses of existing oral agents have resulted in novel therapeutic approaches, which can provide long-term therapy and sustained remission.

Systemic Antibiotic Therapy for Acne: A Review

Acne is a multifactorial disease of the pilosebaceous unit in the skin. Four contributing pathogenic factors need to be elucidated and include excess sebum production, follicular hyperkeratinization, colonization of the pilosebaceous unit by Propionibacterium acnes.

Treatments Of Choice For Bullous Pemphigoid

Bullous pemphigoid (BP) is the most frequently occurring autoimmune blistering disease in Europe and North America. Although it is primarily a disease of the elderly, children and young adults can also develop it.

Perspectives on Isotretinoin and the Canadian Consensus Guidelines on Treatment of Acne

Treatment objectives and pharmacoeconomic considerations are important when developing guidelines that are effective and rational. Canadian Acne Treatment Guidelines were last published in 1995. New guidelines were recently developed to incorporate therapeutic advances and data from more recent studies.

POPULAR

Advertisement